(Q38096996)

28 August 2017

Mipomersen sodium: first global approval (English)

1 reference

28 August 2017

mipomersen parent acid

1 reference

3

Kate McKeage

1 reference

28 August 2017

Philip Hair

1

1 reference

PubMed ID

23564617

28 August 2017

Fiona Cameron

series ordinal

2

1 reference

28 August 2017

1 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

73

1 reference

28 August 2017

5

1 reference

28 August 2017

487-493

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0042-2

28 August 2017

0 references

cites work

Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Antisense oligonucleotides for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0042-2

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

21 January 2018

1 reference

12 December 2020

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

1 reference

12 December 2020

Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia

1 reference

12 December 2020

Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

1 reference

12 December 2020

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

1 reference

12 December 2020

10.1007/S40265-013-0042-2

Identifiers

DOI

1 reference

PubMed ID

23564617

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23564617